✦ LIBER ✦

Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden

✍ Scribed by Kristian Neovius; Katharina Buesch; Kristina Sandström; Martin Neovius

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Palivizumab for respiratory syncytial vi

✍ Jennifer H. Lofland; Suzanne M. Touch; John P. O'Connor; Mary Lou Chatterton; El 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 890 KB

PIN24 COST-EFFECTIVENESS OF RESPIRATORY

✍ L.B. Weiner; M.J. Polak; A. Masaquel; P.J. Mahadevia 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

PIN35 COST-EFFECTIVENESS ANALYSIS OF PAL

✍ S Ikeda; M Kobayashi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Impact of palivizumab on expected costs

✍ Albert Marchetti; Helen Lau; Raf Magar; Liping Wang; Giovanna Devercelli 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 993 KB

Cost-effectiveness of potential infant v

✍ M.J. Meijboom; M.H. Rozenbaum; A. Benedictus; W. Luytjes; M.C.J. Kneyber; J.C. W 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 583 KB

Safety of Palivizumab in Preterm Infants

✍ J. R. Groothuis 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 109 KB